Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIV-infected adults. - Wikidata - wikimedia - TriplyDB

Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIV-infected adults.

Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIV-infected adults.

http://www.wikidata.org/entity/Q39098346

about

CCR5 monoclonal antibodies for HIV-1 therapy Humanized PA14 (a monoclonal CCR5 antibody) for treatment of people with HIV infection Monoclonal CCR5 antibody for treatment of people with HIV infection PRO 140 (a CCR5 monoclonal antibody) for treatment in people with HIV infection Crystal Structure of HIV-1 Primary Receptor CD4 in Complex with a Potent Antiviral Antibody Anti-HIV-1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody.Phase 2a study of the CCR5 monoclonal antibody PRO 140 administered intravenously to HIV-infected adults.In vitro selection and characterization of HIV-1 variants with increased resistance to sifuvirtide, a novel HIV-1 fusion inhibitor.CCR5 antibodies HGS004 and HGS101 preferentially inhibit drug-bound CCR5 infection and restore drug sensitivity of Maraviroc-resistant HIV-1 in primary cells.Natural anti-CCR5 antibodies in HIV-infection and -exposure Clinical use of CCR5 inhibitors in HIV and beyond The critical need for alternative antiretroviral formulations, and obstacles to their development.CCR5: From Natural Resistance to a New Anti-HIV Strategy.Neutralization properties of simian immunodeficiency viruses infecting chimpanzees and gorillas.CCR5 blockade is well tolerated and induces changes in the tissue distribution of CCR5+ and CD25+ T cells in healthy, SIV-uninfected rhesus macaques Monoclonal antibody-based candidate therapeutics against HIV type 1.Antiretroviral drugs: critical issues and recent advances Towards HIV-1 remission: potential roles for broadly neutralizing antibodies.Topical application of entry inhibitors as "virustats" to prevent sexual transmission of HIV infection.Human Immunodeficiency Virus Immune Cell Receptors, Coreceptors, and Cofactors: Implications for Prevention and Treatment.Strategic addition of an N-linked glycan to a monoclonal antibody improves its HIV-1-neutralizing activity.Human monoclonal antibodies and engineered antibody domains as HIV-1 entry inhibitors.Pharmacotherapy of HIV-1 Infection: Focus on CCR5 Antagonist Maraviroc.Novel compounds for the treatment of HIV type-1 infection.Biology and clinical relevance of chemokines and chemokine receptors CXCR4 and CCR5 in human diseases.Targeting the protein-protein interactions of the HIV lifecycle.Conformational HIV-1 envelope on particulate structures: a tool for chemokine coreceptor binding studies.Immunotherapeutic restoration in HIV-infected individuals.Pharmacological modulation of chemokine receptor function.Candidate antibody-based therapeutics against HIV-1.Effect of HIV-1 subtype and tropism on treatment with chemokine coreceptor entry inhibitors; overview of viral entry inhibition.Engineering broadly neutralizing antibodies for HIV prevention and therapy.Epitope switching as a novel escape mechanism of HIV to CCR5 monoclonal antibodies.Synergistic inhibition of R5 HIV-1 by maraviroc and CCR5 antibody HGS004 in primary cells: implications for treatment and prevention Universal antiretroviral regimens: thinking beyond one-pill-once-a-day.Distinct HIV-1 Neutralization Potency Profiles of Ibalizumab-Based Bispecific Antibodies.Opportunities for therapeutic antibodies directed at G-protein-coupled receptors.Development of tetravalent, bispecific CCR5 antibodies with antiviral activity against CCR5 monoclonal antibody-resistant HIV-1 strains.Circular CCR5 peptide conjugates and uses thereof (WO2008074895).Epitope mapping of ibalizumab, a humanized anti-CD4 monoclonal antibody with anti-HIV-1 activity in infected patients.

P2860

Q22242739-ACB0735C-91BB-4A25-8ACB-E8CB16664E34 Q24194805-D620E3AF-37EF-41CD-A3AA-BAD4D83AAA37 Q24235689-49DDCDDE-5FB7-4A61-A019-624200A1FE96 Q24239870-D1DE6B7F-1149-4C91-9237-A0BF69D7829E Q27666197-503E69EE-40CC-4A60-9E06-D4B4B0DEC919 Q33798442-0193E9A9-AA7A-4FC0-9291-D4C112EE2EC7 Q34150882-8B83EB15-1B49-464D-8D2B-8CE042D80BF5 Q34536817-8BDE9DFC-B378-416C-AC1E-3803A6A4BA8A Q34574397-F8712D34-914C-4506-AF86-1D06F30FD99E Q35018133-8259E2CD-3DF7-48BA-8C14-1F6CB8FF852C Q35018145-416201AD-A67A-4959-9C7E-70C822856084 Q35164438-A3C150A8-20EA-49B7-B7F5-0377A1699AE7 Q35260605-F8A4C631-8975-4EE4-9F14-A3DFB7215B1F Q35677620-ABB8F363-61E5-44B4-A04A-935396A8F566 Q35693333-EEAEC5FF-B3D9-466C-B71B-33176019DEDA Q35904501-290BEC66-AF02-4213-9B8B-1F45CFFD4DB6 Q36020992-82D99544-53A9-4253-9E87-3E15E632B7C9 Q36515149-3CC41821-B2AD-444C-B4E5-6318C2FE4409 Q37088591-C98C3A03-B029-4503-9908-BE3E04270D9F Q37102101-3DFD429F-E070-41BE-889C-86852ABF5C69 Q37302902-FC8179E8-C8FE-4840-B322-4A487FE0DDEA Q37388409-FC70F8EE-5D2A-4EDA-BF4B-F4E5CC9B4D6B Q37421895-E7F85EAE-B74B-4B89-869E-E1FDFE3E06B4 Q37502492-EABBD578-47C2-44FE-AF83-6D22AA9021F0 Q37599363-C44357E7-448A-4129-AD48-DF39827F4FA2 Q37820252-CD968A0A-709D-4AFD-A155-7B48123D2F7D Q37834097-38354E7D-C913-425A-B0E9-208B2A03061E Q37842335-0D305496-43DB-486C-B369-51300790243A Q37893687-5BBBC5C0-454D-4A11-AA2B-BDFE9DA4D1C8 Q37998496-BED2220D-382F-44C9-B182-3132582F6999 Q38196457-1B44D4E7-42E0-4E9D-8333-AC0BECB15F47 Q38717198-9D69FDCF-6008-4ED7-B198-5A667DBFE59F Q39103386-BB4F9FF6-ED45-4259-AE30-5313195CB7AD Q39161979-FA5DC4CC-0441-4529-9A20-9381F03BF53E Q39215169-A76A43D3-89B5-449A-A750-07C790280FB0 Q39238361-F32AD141-1E55-4806-967C-580E5B7610F2 Q39433833-8AD2FDED-28FC-416F-9623-5FE04610949D Q39435224-FE20FCE9-EF06-44AE-9E67-E8D9193F165E Q39477959-A8CE536D-0C72-4566-830B-59D071A96F9D Q41762652-1BB6487E-250B-47D9-B6F0-BB07D1349EA0

P2860

Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIV-infected adults.

http://www.wikidata.org/entity/Q39098346

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

2008年论文

@zh

2008年论文

@zh-cn

name

Antiviral activity of single-d ...... ibody, in HIV-infected adults.

@en

Antiviral activity of single-d ...... ibody, in HIV-infected adults.

@nl

type

label

Antiviral activity of single-d ...... ibody, in HIV-infected adults.

@en

Antiviral activity of single-d ...... ibody, in HIV-infected adults.

@nl

prefLabel

Antiviral activity of single-d ...... ibody, in HIV-infected adults.

@en

Antiviral activity of single-d ...... ibody, in HIV-infected adults.

@nl

P1433

Q39098346-1786B89C-8852-4999-A398-DD24A2797297

P1476

Q39098346-A0571866-09B0-4511-8317-1735B0C837D2

P2093

Q39098346-05BF4190-B0BE-403A-8F13-EC3132C5CF81

Q39098346-1002C26A-5B39-4A36-87BF-84ED59B1A247

Q39098346-1CB62D69-6AE9-4255-BE1D-9CC14DD9B7B6

Q39098346-29DCDCAD-F552-4102-8F65-D977CC7DDFA5

Q39098346-2C833ABD-D1A1-4889-B58B-98E327AD11C3

Q39098346-2D500BAD-26D2-4661-A788-2D9EE349DD98

Q39098346-328E0056-E65E-482E-949A-5FF869A17F38

Q39098346-32DB10A6-D502-433C-8D48-4ADAC7C476CE

Q39098346-4265DE57-0D92-4549-9B44-E274EFA2D642

Q39098346-4FA422B7-C3F7-4171-80DD-A671BEC0D69E

P2860

Q39098346-024D23DE-3733-4EC8-A701-034DF5670D5A

Q39098346-08130E3D-E720-49AE-BE8A-23F535A917CA

Q39098346-0A41E0AF-A590-4076-B669-1A77B0CEFCAC

Q39098346-10F313D0-150D-4640-8184-9AB0E261DDC8

Q39098346-136797CC-C92C-4B3A-9587-E046C88C64CF

Q39098346-16608B58-8DAF-48FB-9F82-8DBF8CA229FA

Q39098346-234C8F7B-F144-481A-B9BF-AEB915052040

Q39098346-28609DFB-502C-4E22-9F91-5286A52984FD

Q39098346-346174B8-E889-4C54-8C82-4917E1CAB987

Q39098346-4F1300C4-E049-464A-A1B2-C2DEACFB6019

P304

Q39098346-6ACA6D4C-58D5-4D5C-B961-12AA0CAA8804

P31

Q39098346-25D53CD5-48A3-49E4-9EE7-A6B8F7E27A52

P356

Q39098346-1C21C921-4C38-4933-A393-56B033C060A1

P407

Q39098346-2AC4B43C-4D6A-4D7D-830E-02BCCB7A4220

P433

Q39098346-0A99F799-A0A7-451A-BEF9-49DD0589647B

P478

Q39098346-069D5814-E4E7-4AC7-A079-4D78C85A7FFC

P50

Q39098346-53907D23-C42C-47C6-95FD-F87C455B1154

P577

Q39098346-E50A1327-8658-45EC-A2AA-A194DDE3BBD9

P5875

Q39098346-FFE36152-1647-49C4-8E34-3BA91C93AE4E

P698

Q39098346-7540160F-B222-4948-918E-DBDF9812B9A9

P921

Q39098346-1AC36FB1-7E64-4079-86C9-A398A546CBEB

P356

P1433

The Journal of Infectious Diseases

P1476

Antiviral activity of single-d ...... tibody, in HIV-infected adults

@en

P2093

Alton B Kremer

http://www.w3.org/2001/XMLSchema#string

Barry S Zingman

http://www.w3.org/2001/XMLSchema#string

Hans Kroger

http://www.w3.org/2001/XMLSchema#string

Hieu Ly

http://www.w3.org/2001/XMLSchema#string

Jeffrey M Jacobson

http://www.w3.org/2001/XMLSchema#string

Jose D Murga

http://www.w3.org/2001/XMLSchema#string

Joseph J Stavola

http://www.w3.org/2001/XMLSchema#string

Mahesh C Patel

http://www.w3.org/2001/XMLSchema#string

Margaret A Fischl

http://www.w3.org/2001/XMLSchema#string

Marti Michael

http://www.w3.org/2001/XMLSchema#string

P2860

HIV-1 Entry Cofactor: Functional cDNA Cloning of a Seven-Transmembrane, G Protein-Coupled Receptor

Identification of a major co-receptor for primary isolates of HIV-1

Potent antiviral synergy between monoclonal antibody and small-molecule CCR5 inhibitors of human immunodeficiency virus type 1

Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America

Elimination mechanisms of therapeutic monoclonal antibodies

Antiviral activity, pharmacokinetics and safety of vicriviroc, an oral CCR5 antagonist, during 14-day monotherapy in HIV-infected adults

A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5

CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5

P304

1345-1352

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1086/592169

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

198

http://www.w3.org/2001/XMLSchema#string

P50

Carl Fichtenbaum

P577

2008-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23237531

http://www.w3.org/2001/XMLSchema#string

P698

18771406

http://www.w3.org/2001/XMLSchema#string

P921